WASHINGTON — For the last six months, Congress seemed to be sailing towards the uncharacteristically smooth passage of a massive, multibillion-dollar bill to fund the Food and Drug Administration.
That all changed late last week when one powerful lawmaker, Sen. Richard Burr (R-N.C.), came out in opposition to the so-called user fee reauthorization bill he helped craft — and supported throughout the committee process.